11h agoReutersBULLISH 73Product/PR
Archived explainer. For the current picture see today's GMAB page.
Why Is GENMAB A/S ADR (GMAB) Stock Up Today?
By the Top Tier Newswire AI Desk · October 6, 2026 at 12:08 AM ET · reviewed against 15 wire stories
GENMAB A/S ADR (GMAB) is up +10.73% in the latest session. Our newswire has captured 15 stories on GMAB across 10 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why GMAB stock is up today
Genmab A/S ADR (GMAB) surged 10.73% to $38.48 in the session, driven by positive clinical trial data for its cancer drug candidate in combination with a standard treatment. The stock climbed on news that the drug combination significantly improved progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma. The results from the phase 3 EPCORE DLBCL-2 study were described as the first for a bispecific antibody therapy in this setting.
What Happened
Genmab and AbbVie announced that epcoritamab, when combined with R-CHOP, reduced the risk of disease progression or death by 51% compared to R-CHOP alone. The trial marked a milestone as the first phase 3 study of a bispecific antibody combination therapy to show a statistically significant and clinically meaningful improvement in progression-free survival for frontline treatment of diffuse large B-cell lymphoma. This development has positioned Genmab’s Epkinly as a potential first-line treatment for B-cell lymphoma, boosting investor confidence in the drug’s commercial prospects.
What The Data Shows
The stock has moved up 3.3% over the last eight sessions, from $34.83 to $35.99, and closed at $38.48, above its 52-week high of $35.91. The market cap is $20.3 billion, with a low P/E ratio of 2.7 and a net margin of 19.1%. Recent trading activity included one congressional trade, a buy of $1,001 to $15,000 by Alan Armstrong on March 30. The stock also printed 20 fresh 52-week highs on October 5, indicating strong near-term momentum.
What To Watch
The company is not scheduled to report earnings in the near term. Investors may monitor the breadth of coverage and any further updates on the drug’s regulatory pathway or additional clinical data.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
GMAB by the numbers
Last: $38.48Session: +10.73%7 sessions: +3.34%Coverage: 15 stories / 10 sourcesAI sentiment: 66/100 (bullish)Mkt cap: $20.3BP/E: 2.752w: $23.62 to $35.91
The headlines behind the move
12h agoInvestors.comBULLISH 67Product/PR
AbbVie Partner Flies Sky-High On News For Its $3 Billion Cancer Contender
The addition of Genmab's Epkinly to a standard cocktail of drugs helped lymphoma patients live longer before worsening.
13h agoSeeking AlphaBULLISH 73Product/PR
Genmab, AbbVie data boosts Epkinly as first-line B-cell lymphoma treatment
Genmab and AbbVie’s Epkinly + R-CHOP cut progression/death risk 51% in phase 3 DLBCL trial vs R-CHOP alone. Read more here.
14h agoInvesting.com MarketsBULLISH 73Product/PR
Genmab stock surges 11% on positive cancer drug trial data
Genmab stock surges 11% on positive cancer drug trial data
14h agoThe FlyBULLISH 67Product/PR
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
14h agoPR NewswireBULLISH 73Product/PR
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the...
14h agoGlobeNewswireBULLISH 73Product/PR
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and...
18h agoMarketChameleonNEUTRAL 50General
Genmab discloses Darwin Global stake at 5.11% of voting rights
Genmab disclosed that Darwin Global Management Limited controls voting rights attached to 3,188,361 shares—5.11% of Genmab’s voting rights—as of September 28, 2026. The announcement is a regulatory major-shareholder notice rather than a business or pipeline update, with GMAB trading at $35.70 as of 11:04 AM.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on GMAB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier GMAB move explainers: 2026-10-06 · 2026-10-05